对98例局部晚期乳腺癌（IIIA-IIIB期）患者采用诱导（新辅助）化疗、巩固化疗、激素治疗以及外照射和组织间照射相结合的保守治疗结果。
Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB).
作者信息
Jacquillat C, Baillet F, Weil M, Auclerc G, Housset M, Auclerc M, Sellami M, Jindani A, Thill L, Soubrane C
机构信息
Service d'Oncologie Médicale, Hopital de la Salpétrière, Paris, France.
出版信息
Cancer. 1988 May 15;61(10):1977-82. doi: 10.1002/1097-0142(19880515)61:10<1977::aid-cncr2820611008>3.0.co;2-n.
Ninety-eight patients with locally advanced breast cancer (Stage IIIA-IIIB) were entered into a pilot study combining intensive induction (neoadjuvant) chemotherapy (VTMFAP) with or without hormonochemotherapy, external and interstitial radiotherapy, and consolidation chemotherapy with or without hormonochemotherapy. Tumor regression over 50% was observed in 91% patients after chemotherapy, and complete clinical remission occurred in 100% patients after irradiation. The rate of local relapse is 13%. The 3-year disease-free survival is 62% and 3-year global survival is 77%. Initial chemotherapeutic tumor regression greater than 75% is the main predictive factor for disease-free survival.
98例局部晚期乳腺癌（ⅢA-ⅢB期）患者进入一项试点研究，该研究将强化诱导（新辅助）化疗（VTMFAP）联合或不联合激素化疗、外照射和组织间插植放疗，以及巩固化疗联合或不联合激素化疗。化疗后91%的患者肿瘤消退超过50%，放疗后100%的患者实现临床完全缓解。局部复发率为13%。3年无病生存率为62%，3年总生存率为77%。初始化疗后肿瘤消退大于75%是无病生存的主要预测因素。
Zotero 插件